New opportunities of therapeutic hyperthermia (literature review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


An electronic search for publications on the results of the use of hyperthermia in medicine was carried out using the Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka,RSCI, international and regional journals, materials of international congresses, congresses and conferences.

The review analyzes the results of experimental and clinical studies of the therapeutic effect of hyperthermia or in various non-inflammatory diseases. Experimental studies have shown a pronounced damaging effect of hyperthermia on some types of parasites and therapeutic effect on mice genetically predisposed to type 1 and 2 diabetes mellitus. Clinical studies have shown that hyperthermia significantly improves the condition of patients with cardiovascular and pulmonary insufficiency, depressive syndrome, chronic fatigue syndrome, psoriasis, benign prostatic hyperplasia, limb lymphedema, post-radiation fibrosis and Peyronie's disease. It has been shown that the effectiveness of hyperthermia is associated with a wide range of biological and physiological reactions of cells and tissues to heat exposure, including the expression of heat shock proteins. At the same time, the results obtained in an experiment and in a clinic without randomization require further research and confirmation.

Full Text

Restricted Access

About the authors

Orazakhmet K. Kurpeshev

Siberian Research Institute of Hyperthermia

Author for correspondence.
ORCID iD: 0000-0003-3219-1596
SPIN-code: 2467-6046

MD, Dr. Sci. (Med.)

Russian Federation, Iskitim-5, Novosibirsk region


  1. Fever Therapy. Abstracts and Discussions of papers presented at the First International Conference on Fever Therapy. Ed.: W.M.Simpson, W.Bierman, Ch.M. Carpenter and P.B. Hoeber. New York, 1937. doi: 10.1097/00007611-193806000-00035
  2. Velikov VK, Sheina AN. Pyrotherapy. The Great Medical Encyclopedia. Ed. by B.V. Petrovsky. 3rd ed. Moscow: Soviet Encyclopedia; 1974–1989. Vol. 19. Р. 258–259. (In Russ).
  3. Kurpeshev OK, van der Zee J. Experimental basis for the use of hyperthermia in oncology. Medical radiology and radiation safety. 2018;63(1):57–77. (In Russ) doi: 10.12737/article_5a8556b4be3e24.36808227
  4. Suvernev AV, Ivanov GV. Intensive thermotherapy. Novosibirsk: Geo; 2014. 106 p. (In Russ).
  5. Gũllũoğlu BM, Bekrakı A, Çerıkçıoğlu N, Sõyletır G. Immunologic influences of hyperthermia in a rat model of obstructive jaundice. Digestive Diseases and Sciences. 2001;46(11):2378–2384.
  6. Pearson J, Low DA, Stöhr E, et al. Hemodynamic responses to heat stress in the resting and exercising human leg: insight into the effect of temperature on skeletal muscle blood flow. Am J Physiol Regul Integr Comp Physiol. 2011;300(3):R663–R673. doi: 10.1152/ajpregu.00662.2010
  7. Kurpeshev OK. Hyperthermia in the treatment of patients with non-oncological diseases (literature review). Physiotherapy, Balneology and Rehabilitation. 2020;19(6):400–412. (In Russ).
  8. Grazú V, Silber AM, Moros M, et al. Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections. Int J Nanomedicine. 2012;7:5351–5360.
  9. Sazgarnia A, Taheri AR, Soudmand S, et al. Antiparasitic effects of gold nanoparticles with microwave radiation on promastigots and amastigotes of Leishmania major. Int J Hyperthermia. 2013;29(1):79–86. doi: 10.3109/02656736.2012.758875
  10. Raisov TK, Orazalina NM, Kurpeshev OK. Effect of hyperthermia on trichinae viability. The 14th int. sympos. on clinical hyperth. Dubna; 1991. P. 55.
  11. Capitano ML, Ertel BR, Repasky EA, Ostberg JR. Fever-range whole body hyperthermia prevents the onset of type I diabetes in non-obese diabetic mice. Int J Hyperthermia. 2008;24(2):141–149. doi: 10.1080/02656730701858289
  12. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24:5434–5446.
  13. Sasaki KR, Morino-Koga S, Adachi H, et al. Hyperthermia with mild electrical stimulation protects pancreatic β-cells from cell stresses and apoptosis. Diabetes. 2012;61(4):838–847.
  14. Kondo T, Motoshima H, Igata M, et al. The role of heat shock response in insulin resistance and diabetes. Diabetes Metab J. 2014;38(2):100–106. doi: 10.4093/dmj.2014.38.2.100
  15. Kokura S, Adachi S, Manabe E, et al. Whole body hyperthermia improves obesity-induced insulin resistance in diabetic mice. Int J Hyperthermia. 2007;23(3):259–265.
  16. Tei C, Imamura T, Kinugawa K, et al. Waon therapy for managing chronic heart failure ― results from a multicenter prospective randomized WAON-CHF study. Circulation J. 2016;80(4):827–834. doi: 10.1253/circj.CJ-16-0051
  17. Kihara T, Miyata M, Fukudome T, et al. Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol. 2009;53:214–218.
  18. Tei C, Shinsato T, Miyata M, et al. Waon therapy improves peripheral arterial disease. J Am Coll Cardiol. 2007;50(22):2169–2171. doi: 10.1016/j.jacc.2007.08.025
  19. Umehara M, Yamaguchi A, et al. Repeated waon therapy improves pulmonary hypertension during exercise in patients with severe chronic obstructive pulmonary disease. J Cardiol. 2008;51(2):106–113. doi: 10.1016/j.jjcc.2008.01.004
  20. Kikuchi H, Shiozawa N, Takata S, et al. Effect of repeated waon therapy on exercise tolerance and pulmonary function in patients with chronic obstructive pulmonary disease: a pilot controlled clinical trial. Int J COPD. 2014;(9):9–15.
  21. Rolls ET, Grabenhorst F, Parris BA. Warm pleasant feelings in the brain. Neuroimage. 2008;41(4):1504–1513.
  22. Raison CL, Hale MW, Williams LE, et al. Somatic influences on subjective well·being and affective disorders: the convergence of thermosensory and central serotonergic systems. Front Psychol. 2015;5:1580. doi: 0.3389/fpsyg.2014.01580
  23. Hale MW, Lowry CA. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology (Berl). 2011;213(2-3):243–264.
  24. Lowry CA, Hale MW, Evans AK, et al. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann NY Acad Sci. 2008;1148:86–94.
  25. Robins HI, Kalin N, Shelton SE, et al. Rise in plasma beta-endorphin, ACTH, and cortisol in cancer patients undergoing whole body hyperthermia. Horm Metab Res. 1987;19:441–443. doi: 10.1055/s-2007-1011847
  26. Hanusch KU, Janssen CH, Billheimer D, et al. Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling. Am J Psychiatry. 2013;170(7):802–804.
  27. Jansen CW, Lowry CA, Mehl MR, et al. Whole-Body hyperthermia for the Treatment of Major Depressive Disorder. A Randomized Clinical Trial. JAMA Psychiatry. 2016;73(8):789–95. doi: 10.100l/jamapsychiatry.2016.1031
  28. Hanusch KU, Janssenb CW. The impact of whole-body hyperthermia interventions on mood and depression ― are we ready for recommendations for clinical application? Int J Hyperthermia. 2019;36(1):572–580. doi: 10.1080/02656736.2019.1612103
  29. Kurpeshev O. Radiofrequency whole body hyperthermia (wbht) in cancer treatment. 28th annual meeting society for thermal medicine, New Orleans, USA; 2011. Abstract 0081.
  30. Balluzek FB, Balluzek MF, Vilensky VI. Controlled therapeutic hyperthermia. St. Petersburg; 2004. 248 p. (In Russ).
  31. Afari N, Buchwald D. Chronic fatigue syndrome: review. Am J Psychiatry 2003;160:221–236.
  32. Soejima Y, Munemoto T, Masuda A, et al. Effects of Waon therapy on chronic fatigue syndrome: a pilot study. Intern Med. 2015;54(3):333–338. doi: 10.2169/internalmedicine.54.3042
  33. Munemoto T, Soejima Y, Masuda A, et al. Increase in the regional cerebral blood flow following Waon therapy in patients with chronic fatigue syndrome: a pilot study. Intern Med. 2017;56:1817–1824. doi: 10.2169/internalmedicine.56.8001
  34. Boreham DR, Gasmann HC, Mitchel RE. Water bath hyperthermia is a simple therapy for psoriasis and also stimulates skin tanning in response to sunlight. Int J Hyperthermia. 1995;11(6):745–754. doi: 10.3109/02656739509052332
  35. Leviav A, Wolf R, Vilan A. Treatment of psoriasis with light and heat energy (LHE): a preliminary study. Dermatology Online Journal. 2004;10(2):4. doi: 10.5070/D33r84w3tx
  36. Coleman W, Lowe N. Ultrasound-induced hyperthermia as adjuvant therapy for palmoplantar psoriasis. J Dermatolog Treatment. 2009;2(1):7–10. doi: 10.3109/09546639109089045
  37. Krasnyak SS. Pathogenetic therapy of benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Experimental and Clinical Urology. 2020;4:66–74. (In Russ). doi: 10.29188/2222-8543-2020-13-4-66-74
  38. Kurpeshev OK, Konoplyannikov AG. Local electromagnetic hyperthermia of prostate adenoma. Medical radiology. 1991;36 (9):22–25. (In Russ).
  39. Yerushalmi A, Singer D, Katsnelson R, et al. Localised deep microwave hyperthermia in the treatment of benign prostatic hyperplasia: long-term assessment. Br J Urol. 1992;70(2):178–182.
  40. Apolikhin OI. Application of methods of hyperthermia, thermotherapy, thermal ablation in the treatment of benign prostatic hyperplasia [dissertation abstract]. Moscow; 1996. 52 p. (In Russ).
  41. Brehmer M, Baba S. Transurethral microwave thermotherapy: how does it work? J Endourol. 2009;14(8):611–615. doi: 10.1089/end.2000.14.611
  42. Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12(9):CD004135. doi: 10.1002/14651858.CD004135.pub3
  43. Sigel YI, Zaidel L, Linder A. The histopatology changes of beinign prostatic hyperplasia after hyperthermia treatment failure ― a controlled study. J Strahlenther Oncol. 1990;166(8):533.
  44. Kurpeshev OK, Tsyb AF, Mardynsky YuS. Transrectal electromagnetic hyperthermia of benign prostatic hyperplasia and chronic prostatitis. Guidelines. Obninsk; 2003. 21 p. (In Russ).
  45. Barbalias GA, Liatsikos EN. Transrectal microwave hyperthermia for patients with benign prostatic hyperplasia. Int J Urol. 1998;5(2):157–162.
  46. Perugia G, Liberti M, Vicini P, et al. Use of local hyperthermia as prophylaxis of fibrosis and modification in penile length following radical retropubic prostatectomy. Int J Hyperthermia. 2005;21(4):359–365.
  47. Borodin YI, Lyubarsky VV, Morozov MS. Guidelines for clinical lymphology. Moscow: МИА; 2010. 208 p. (In Russ).
  48. Liu NF, Olszewski W. The influence of local hyperthermia on lymphedema and lymphedematous skin of the human leg. Lymphology. 1993;26(1):28–37.
  49. Campisi C, Boccardo F, Tacchella M. Use of thermotherapy in management of lymphedema: clinical observations. Int J Angiol. 1999;8(1):73–75. doi: 10.1007/BF01616849
  50. Ohkuma M. Treatment of peripheral lymphoedema by concomitant application of magnetic fields, vibration and hyperthermia: a preliminary report. Lymphology. 2002;35:87–90.
  51. Li K, Xu H, Liu NF, et al. Far-infrared ray for treating chronic lower extremity lymphedema with dermatolymphangioadenitis: a postoperative complication of gynecological tumor resection. Arch Gynecol Obstetrics. 2017. Ausgabe 6.
  52. Li K, Zhang Z, Liu NF, et al. Far-infrared radiation thermotherapy improves tissue fibrosis in chronic extremity lymphedema. Lymphatic Research and Biology. 2018;16(3):248–257. doi: 10.1089/lrb.2016.0057
  53. Kurpeshev OK. Radiobiological analysis of the development of early and late radiation injuries. Medical Radiology. 1984;29(3):54–64. (In Russ).
  54. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
  55. Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010;97:149–161.
  56. Arankalayil MJ, Cohen EP, Wilkins RC, et al. Radiation-induced fibrosis: mechanisms and opportunities to mitigate. Report of an NCI workshop, September 19, 2016. Radiat Res. 2017;188:1–20.
  57. Kurpeshev OK, Pasov VV, Kurpesheva AK. Treatment of late radiation injuries using local radiofrequency hyperthermia. Medical Radiology and Radiation Safety. 2014;59(4):53–57. (In Russ).
  58. Cassutti V, Ballerini M, Baronzio GH, Szasz O. AndroTherm application for Peyronie disease (Phase I/II study). Oncothermia J. 2012;5:11–22.
  59. Ballerini M, Baronzio GH, Capito G, et al. AndroTherm application for "La Peyronie" disease. Oncothermia J. 2013;7:182–188.
  60. Perugia G, Liberti M, Vicini P, et al. Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study. Int J Hyperthermia. 2005;21(4):367–374. doi: 10.1080/02656730500133892
  61. Peyronie’s Disease: American Urological Association (AUA) Guideline (Panel Members). J Urol. 2015;194(3):745–753. doi: 10.1016/j.juro.2015.05.098
  62. Cusmanich CC. Treatment of peyronie’s disease with hyperthermia, vitamin D and Testosterone: a pilot randomized controlled trial, running status, ethics approval: ethic committee of Hospital de Clinicas da Universidade Federal do Parana (Brazil), Curitiba, Brazil; 2007.
  63. Biro S, Masuda A, Kihara T, Tei C. Clinical implications of thermal therapy in lifestyle-related diseases. Exp Biol Med. 2003;228(10):1245–1249.
  64. Kokura S, Adachi S, Mizushima K, et al. Gene expression profiles of diabetic mice treated with whole body hyperthermia: a high-density DNA microarray analysis. Int J Hyperthermia. 2010;26(2):101–107.
  65. Sebők J, Édel Z, Váncsa S, et al. Heat therapy shows benefit in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Hyperthermia. 2021;38(1):1650–1659. doi: 10.1080/02656736.2021.2003445
  66. Oosterveld FG, Rasker JJ, Landkroon MF, et al. Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol. 2009;28:29–34. doi: 10.1007/s10067-008-0977-y
  67. Lyon MS, Milligan C. Extracellular heat shock proteins in neurodegenerative diseases: new perspectives. Neuroscience Letters. 2019;711:134462. doi: 10.1016/j.neulet.2019.134462

Supplementary files

Supplementary Files
1. Fig. 1. Survival of L. major promastigotes with or without gold nanoparticles after microwave hyperthermia of different duration [9].

Download (42KB)
2. Fig. 2. Cytotoxic activity of spleen natural killer cells in different groups of mice [11].

Download (38KB)
3. Fig. 3. Plasma glucose (a) and insulin (b) levels in mice: obese mice without general hyperthermia (untreated db/db); obese mice exposed to general hyperthermia (WBH-treated db/db); mice without obesity and not exposed to general hyperthermia (untreated db/+) [15].

Download (89KB)
4. Fig. 4. The frequency of rehospitalization or death of patients due to heart failure in groups during a 5-year follow-up. Ordinate: death or re-hospitalization, %; abscissa: time, month [17].

Download (33KB)
5. Fig. 5. Diseases of peripheral arteries indicators before (1) and after 10 weeks the whole body hyperthermia course (2): a ― pain assessment on a visual analogue scale (10 ― severe pain, 0 ― no pain) (n=20); b ― 6 minute walk, meter (n=18); c ― ankle-brachial index (n=31); d ― laser Doppler blood flow imaging (n=28) [18].

Download (258KB)
6. Fig. 6. Efficacy of whole body hyperthermia versus placebo on the Hamilton point scale for 6 weeks after exposure [27].

Download (58KB)

Copyright (c) 2022 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 77 - 9245 от 22.06.2001
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies